Physical Fitness
Walking your way to easier breathing
CSL Behring understands that an important part of caring for "the whole you" is
helping you be as active and healthy as possible. One easy and fun way to do that
is simply by walking. Walking improves oxygen delivery throughout your body, which
means the lungs don't have to work as hard, energy levels increase, and fatigue
decreases. A regular walking program could also8,14:
- Improve your quality of life
- Increase your stamina
- Lengthen your life expectancy
The many benefits of walking are why CSL Behring created My Steps for Healthy Living,
a free, no-obligation program designed exclusively for Alphas.
My Steps for Healthy Living
The "My Steps" program challenges you to adopt a regular walking program and then
walk a little more each day. Here's how the program works:
- You will receive a free pedometer and a log book to help you track how many steps
you take each day
- At the end of each month, record your total number of steps on a "My Steps" report
card and mail it to CSL Behring,
or record your steps online
- The goal is to help you increase your number of steps by 10% each month
- Regardless of whether you reach this goal, you will receive a motivational reward
and a new report card for the following month
CSL Behring encourages all people with Alpha-1 to keep moving forward. Any step
you take in the "My Steps" program is a positive step, and CSL Behring will be there
to encourage you every step of the way.
Remember, before beginning any physical activity, consult with your doctor to make
sure the activity is right for you.
Register for "My Steps" now!
Important Safety Information
Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available.
Zemaira may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.
In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).
Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.
Please see full prescribing information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.